scholarly journals Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy

2020 ◽  
Vol 19 ◽  
pp. 153601212093495
Author(s):  
Liqin Zhu ◽  
Zhikai Ding ◽  
Xingliang Li ◽  
Hongyuan Wei ◽  
Yue Chen
Keyword(s):  
Targeted Delivery ◽  
Tumor Vasculature ◽  
Current Data ◽  
Research Progress ◽  
Vascular Targeting ◽  
Molecular Scaffolds ◽  
Radiolabeled Peptides ◽  
Successful Approach ◽  
Preclinical And Clinical Studies ◽  
Toxic Reactions

Asn-Gly-Arg (NGR) motifs have vasculature-homing properties via interactions with the aminopeptidase N (CD13) expressed on tumor neovasculature. Numerous NGR peptides with different molecular scaffolds have been exploited for targeted delivery of different compounds for imaging and therapy. When conjugated with NGR, complexes recognize the CD13 receptor expressed on the tumor vasculature, which improves the specificity to tumor and avoids systematic toxic reactions. Both preclinical and clinical studies performed with these products suggest that NGR-mediated vascular targeting is an effective strategy for delivering bioactive amounts of cytokines to tumor endothelial cells. For molecular imaging, radiolabeled peptides have been the most successful approach and have been translated into clinic. This review describes current data on radiolabeled tumor vasculature-homing NGR peptides for imaging and therapy.

scholarly journals Hyaluronic Acid-Coated MTX-PEI Nanoparticles for Targeted Rheumatoid Arthritis Therapy

Crystals ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 321
Author(s):  
Shenghui Zhong ◽  
Peng Liu ◽  
Jinsong Ding ◽  
Wenhu Zhou
Keyword(s):  
Rheumatoid Arthritis ◽  
Hyaluronic Acid ◽  
Targeted Delivery ◽  
High Dose ◽  
One Pot ◽  
Inflammatory Site ◽  
Pei Nanoparticles ◽  
Toxic Reactions

Methotrexate (MTX) is an anchor drug for the treatment of rheumatoid arthritis (RA); however, long-term and high-dose usage of MTX for patients can cause many side effects and toxic reactions. To address these difficulties, selectively delivering MTX to the inflammatory site of a joint is promising in the treatment of RA. In this study, we prepared MTX-PEI@HA nanoparticles (NPs), composed of hyaluronic acid (HA) as the hydrophilic negative electrical shell, and MTX-linked branched polyethyleneimine (MTX-PEI) NPs as the core. MTX-PEI@HA NPs were prepared in the water phase by a one-pot method. The polymeric NPs were selectively internalized via CD44 receptor-mediated endocytosis in the activated macrophages. In the in vivo mice mode study, treatment with MTX-PEI@HA NPs mitigated inflammatory arthritis with notable safety at a high dose of MTX. We highlight the distinct advantages of aqueous-synthesized NPs coated with HA for arthritis-selective targeted delivery, thus verifying MTX-PEI@HA NPs as a promising MTX-based nanoplatform for treatment of RA.

scholarly journals The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 776
Author(s):  
Fahimeh Faqihi ◽  
Marcus A. Stoodley ◽  
Lucinda S. McRobb
Keyword(s):  
Ischemic Stroke ◽  
Targeted Delivery ◽  
Vascular Malformations ◽  
Thrombus Formation ◽  
Developed Countries ◽  
Coagulation Cascade ◽  
Vascular Targeting ◽  
Systemic Delivery ◽  
Vessel Occlusion ◽  
Vessel Patency

In cardiovascular and cerebrovascular biology, control of thrombosis and the coagulation cascade in ischemic stroke, myocardial infarction, and other coagulopathies is the focus of significant research around the world. Ischemic stroke remains one of the largest causes of death and disability in developed countries. Preventing thrombosis and protecting vessel patency is the primary goal. However, utilization of the body’s natural coagulation cascades as an approach for targeted destruction of abnormal, disease-associated vessels and tissues has been increasing over the last 30 years. This vascular targeting approach, often termed “vascular infarction”, describes the deliberate, targeted delivery of a thrombogenic effector to diseased blood vessels with the aim to induce localized activation of the coagulation cascade and stable thrombus formation, leading to vessel occlusion and ablation. As systemic delivery of pro-thrombotic agents may cause consternation amongst traditional stroke researchers, proponents of the approach must suitably establish both efficacy and safety to take this field forward. In this review, we describe the evolution of this field and, with a focus on thrombogenic effectors, summarize the current literature with respect to emerging trends in “coaguligand” development, in targeted tumor vessel destruction, and in expansion of the approach to the treatment of brain vascular malformations.

scholarly journals Tumor vasculature-targeted delivery of tumor necrosis factor-α*

Cancer ◽  
2008 ◽  
Vol 115 (1) ◽  
pp. 128-139 ◽  
Author(s):  
Anita Tandle ◽  
Engy Hanna ◽  
Dominique Lorang ◽  
Amin Hajitou ◽  
Catherine A. Moya ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Targeted Delivery ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Tumor Vasculature ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth

Oncogene ◽  
2018 ◽  
Vol 37 (29) ◽  
pp. 3967-3980 ◽  
Author(s):  
Khaled Seidi ◽  
Rana Jahanban-Esfahlan ◽  
Hassan Monhemi ◽  
Peyman Zare ◽  
Babak Minofar ◽  
...  
Keyword(s):  
Cell Growth ◽  
Cancer Cell ◽  
Targeted Delivery ◽  
Tumor Vasculature ◽  
Cancer Cell Growth

Adverse reactions during chemotherapy: skin toxicity

2020 ◽  
pp. 28-64
Author(s):  
Maksim Leonidovich Maksimov ◽  
Malika Anarbekovna Ismailova
Keyword(s):  
Skin Toxicity ◽  
Chemotherapeutic Agents ◽  
Current Data ◽  
Antitumor Antibiotics ◽  
Antitumour Agents ◽  
Oncological Diseases ◽  
Dermatological Toxicity ◽  
Mechanisms Of Development ◽  
Toxic Reactions

Chemotherapy of oncological diseases is associated with high toxicity. The occurrence of various toxic reactions during the use of antitumor drugs is explained by the fact that most antitumor medicines are not strictly specific, therefore, their effect can extend not only to tumor cells, but also to normal cells, especially to tissues with rapid proliferation. All antitumour agents have skin toxicity in one form or another. However, for some chemotherapeutic agents, skin toxicity is a kind of «reflection» of certain mechanisms of drugs action, and, in most cases, the severity of dermatological reactions correlates with the effectiveness of chemotherapy. Dermatological toxicity deserves special attention, as it affects the quality of life of cancer patients and, in some cases, may require a dose reduction or even cancellation of chemotherapy. This article presents current data on the mechanisms of development of skin toxicity of routine chemotherapeutic agents, growth factor inhibitors and some antitumor antibiotics, its correction and prevention opportunities.

RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells

2009 ◽  
Vol 17 (6) ◽  
pp. 459-467 ◽  
Author(s):  
Yiguang Wang ◽  
Xun Wang ◽  
Yifei Zhang ◽  
Shijin Yang ◽  
Jiancheng Wang ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Targeted Delivery ◽  
Polymeric Micelles ◽  
Tumor Vasculature

scholarly journals The role of the lymphatic system in the homeostasis of the interstitial fluid in the lung and pleural liquid

2019 ◽  
Vol 18 (1) ◽  
pp. 104-112 ◽  
Author(s):  
G. I. Lobov
Keyword(s):  
Endothelial Cells ◽  
Respiratory System ◽  
Interstitial Fluid ◽  
Lymphatic System ◽  
Lymphatic Vessels ◽  
Current Data ◽  
The Body ◽  
Almost All ◽  
Preclinical And Clinical Studies

Accomplishments in the identifcation of lymphatic endothelial cells and the ability to differentiate them from the endothelial cells of blood vessels have contributed to progress in recent decades in studying the role of the lymphatic system in the body. Preclinical and clinical studies of the last decade have shown that changes in the lymphatic vascular network are observed in almost all lung diseases. At the same time, it remains unclear whether the lymphatic vessels and lung nodes are being part of the overall process of lung remodeling or they make a defnite contribution to the pathogenesis of diseases of the respiratory system. This review presents current data on the morphology and physiology of lymphatic vessels and nodes, their role in the regulation of interstitial fluid homeostasis, lipid transportation and immune responses as well as describes the mechanisms of regulation of the transport function of lymphatic vessels. Data on the role of the lymphatic system of the lungs in the exchange of fluid in the interstitial space of the lungs are presented in the review. The results of studies of the last two decades on the formation and reabsorption of pleural fluid and the role of various lymphatic networks in regulating its volume are described. Finally, modern ideas on the mechanisms of pulmonary edema are outlined and important questions of the lymphatic biology of the respiratory system are identifed, still remaining unanswered today.

scholarly journals Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

2021 ◽  
Vol 11 ◽  
Author(s):  
Yihang Qi ◽  
Li Chen ◽  
Qiang Liu ◽  
Xiangyi Kong ◽  
Yi Fang ◽  
...  
Keyword(s):  
Inflammatory Responses ◽  
Lymphocyte Activation ◽  
Research Progress ◽  
Protein Coding ◽  
Immunotherapy Strategy ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Regulatory Effects ◽  
Preclinical And Clinical Studies ◽  
Lymphocyte Activation Gene

Although various immunotherapies have exerted promising effects on cancer treatment, many patients with cancer continue to exhibit poor responses. Because of its negative regulatory effects on T cells and its biological functions related to immune and inflammatory responses, there has been considerable emphasis on a protein-coding gene named lymphocyte-activation gene 3 (LAG3). Recently, evidence demonstrated marked synergy in its targeted therapy with programmed death-1 and programmed death-1 ligand-1 (PD-1/PD-L1) blockade, and a variety of LAG3 targeted agents are in clinical trials, indicating the important role of LAG3 in immunotherapy. This mini-review discusses preclinical and clinical studies investigating PD-1 pathway blockade in combination with LAG3 inhibition as a potentially more effective immunotherapy strategy for further development in the clinic. This strategy might provide a new approach for the design of more effective and precise cancer immune checkpoint therapies.

Sign in / Sign up

Export Citation Format

Share Document